{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:59Z","timestamp":1792794779358,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ERBP"},{"name":"European Renal Association","id":[{"id":"https:\/\/ror.org\/01zpyjx73","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021081","name":"European Rare Kidney Disease Reference Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The Kidney Disease Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a long-awaited development and the first KDIGO guideline addressing a genetic kidney disease. The approval of tolvaptan as targeted therapy for ADPKD in 2015 marked a pivotal advancement and motivated a structured approach in research and clinical care. The systemic nature of ADPKD guidance for the management of extrarenal manifestations is of special importance for nephrologists and requires interdisciplinary collaboration. In this regard, cysts in other organs, particularly the liver, are the most common extrarenal finding. While most liver cysts are incidental findings on routine imaging, both cyst infections and severe polycystic liver disease accompanying ADPKD come with a high disease burden and challenges in management. In contrast, pancreatic cysts in ADPKD are usually completely asymptomatic, but this raises questions about the need for follow-up. This commentary provides an overview of the most important recommendations and practice points on hepatopancreatic cysts provided by the KDIGO guideline with the aim to contribute to implementation and highlight remaining gaps in guidance, clinical care and research.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf159","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:52:23Z","timestamp":1755085943000},"page":"171-179","source":"Crossref","is-referenced-by-count":7,"title":["KDIGO 2025 ADPKD guideline: a commentary on diagnosis and management of hepatopancreatic manifestations by the ERA Working Group Genes &amp; Kidney"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-0745","authenticated-orcid":false,"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"University of Cologne Department II of Internal Medicine, Faculty of Medicine and University Hospital, , Cologne ,","place":["Germany"]},{"name":"Center for Rare Diseases Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne , Cologne ,","place":["Germany"]},{"name":"Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-4459","authenticated-orcid":false,"given":"Emilie","family":"Cornec-Le Gall","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, H\u00e9modialyse et Transplantation R\u00e9nale, Centre de r\u00e9f\u00e9rence MARHEA, Fili\u00e8re ORKID, CHRU Brest , Brest ,","place":["France"]},{"name":"University of Brest, Inserm , UMR 1078, GGB, Brest ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"University of Cologne Department II of Internal Medicine, Faculty of Medicine and University Hospital, , Cologne ,","place":["Germany"]},{"name":"Center for Rare Diseases Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"University of Groningen Department of Nephrology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1377-9880","authenticated-orcid":false,"given":"Jan","family":"Halbritter","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin Berlin Department of Nephrology and Medical Intensive Care, Charit\u00e9 , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-2496","authenticated-orcid":false,"given":"Richard","family":"Taubert","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, , Hannover ,","place":["Germany"]},{"name":"European Reference Network on Rare Hepatological Diseases (ERN RARE-LIVER)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P H","family":"Drenth","sequence":"additional","affiliation":[{"name":"European Reference Network on Rare Hepatological Diseases (ERN RARE-LIVER)"},{"name":"Amsterdam UMC Department of Gastroenterology and Hepatology, , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025122223464036200_bib1","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2025122223464036200_bib2","doi-asserted-by":"crossref","first-page":"sfae363","DOI":"10.1093\/ckj\/sfae363","article-title":"Liver manifestations in autosomal dominant polycystic kidney disease (ADPKD) and their impact on quality of life","volume":"18","author":"Arjune","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025122223464036200_bib3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jhep.2017.11.024","article-title":"Clinical management of polycystic liver disease","volume":"68","author":"van Aerts","year":"2018","journal-title":"J Hepatol"},{"key":"2025122223464036200_bib4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/ndt\/gfw008","article-title":"Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease","volume":"31","author":"Chebib","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223464036200_bib5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1053\/j.gastro.2015.01.015","article-title":"American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts","volume":"148","author":"Vege","year":"2015","journal-title":"Gastroenterology"},{"key":"2025122223464036200_bib6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ajg.2018.14","article-title":"ACG clinical guideline: diagnosis and management of pancreatic cysts","volume":"113","author":"Elta","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2025122223464036200_bib7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/gutjnl-2018-316027","article-title":"European evidence-based guidelines on pancreatic cystic neoplasms","volume":"67","author":"European Study Group on Cystic Tumours of the Pancreas","year":"2018","journal-title":"Gut"},{"key":"2025122223464036200_bib8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pan.2023.12.009","article-title":"International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas","volume":"24","author":"Ohtsuka","year":"2024","journal-title":"Pancreatology"},{"key":"2025122223464036200_bib9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1148\/radiol.2016151650","article-title":"Pancreatic cysts in autosomal dominant polycystic kidney disease: prevalence and association with PKD2 gene mutations","volume":"280","author":"Kim","year":"2016","journal-title":"Radiology"},{"key":"2025122223464036200_bib10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MPA.0000000000001306","article-title":"Pancreatic cysts and intraductal papillary mucinous neoplasm in autosomal dominant polycystic kidney disease","volume":"48","author":"McNicholas","year":"2019","journal-title":"Pancreas"},{"key":"2025122223464036200_bib11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s002689900086","article-title":"Laparoscopic treatment of nonparasitic liver cysts: adequate selection of patients and surgical technique","volume":"20","author":"Gigot","year":"1996","journal-title":"World J Surg"},{"key":"2025122223464036200_bib12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/SLA.0b013e3181ad83dc","article-title":"Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation","volume":"250","author":"Schnelldorfer","year":"2009","journal-title":"Ann Surg"},{"key":"2025122223464036200_bib13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/jhep.2003.50006","article-title":"Clinical profile of autosomal dominant polycystic liver disease","volume":"37","author":"Qian","year":"2003","journal-title":"Hepatology"},{"key":"2025122223464036200_bib14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","article-title":"Liver involvement in early autosomal-dominant polycystic kidney disease","volume":"13","author":"Hogan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025122223464036200_bib15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2215\/CJN.08660621","article-title":"Volume progression and imaging classification of polycystic liver in early autosomal dominant polycystic kidney disease","volume":"17","author":"Bae","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025122223464036200_bib16","first-page":"81","article-title":"Impact of liver volume on polycystic liver disease-related symptoms and quality of life. United European","volume":"6","author":"Neijenhuis","year":"2018","journal-title":"Gastroenterol J"},{"key":"2025122223464036200_bib17","doi-asserted-by":"publisher","first-page":"100579","DOI":"10.1016\/j.jhepr.2022.100579","article-title":"Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis","volume":"4","author":"Sierks","year":"2022","journal-title":"JHEP Rep"},{"key":"2025122223464036200_bib18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.gastro.2023.12.007","article-title":"Sex, genotype, and liver volume progression as risk of hospitalization determinants in autosomal dominant polycystic liver disease","volume":"166","author":"Sch\u00f6nauer","year":"20243","journal-title":"Gastroenterology"},{"key":"2025122223464036200_bib19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.hpb.2023.04.004","article-title":"Expanding the clinical application of the polycystic liver disease questionnaire: determination of a clinical threshold to select patients for therapy","volume":"25","author":"Barten","year":"2023","journal-title":"HPB (Oxford)"},{"key":"2025122223464036200_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ueg2.12387","article-title":"Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: a multi-centric prospective study","volume":"11","author":"Billiet","year":"2023","journal-title":"United Eur Gastroenterol J"},{"key":"2025122223464036200_bib21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jhep.2022.06.002","article-title":"EASL clinical practice guidelines on the management of cystic liver diseases","volume":"77","author":"European Association for the Study of the Liver","year":"2022","journal-title":"J Hepatol"},{"issue":"2 Suppl","key":"2025122223464036200_bib22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","author":"Kidney Disease: Improving Global Outcomes ADPKD Work Group","year":"2025","journal-title":"Kidney Int"},{"key":"2025122223464036200_bib23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"key":"2025122223464036200_bib24","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025122223464036200_bib25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025122223464036200_bib26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","article-title":"Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease","volume":"157","author":"van Aerts","year":"2019","journal-title":"Gastroenterology"},{"key":"2025122223464036200_bib27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2013.04.055","article-title":"Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data","volume":"145","author":"Gevers","year":"2013","journal-title":"Gastroenterology"},{"key":"2025122223464036200_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40268-021-00342-7","article-title":"Incident gallstones during somatostatin analog treatment are associated with acute biliary complications especially after discontinuation","volume":"21","author":"Aapkes","year":"2021","journal-title":"Drugs R D"},{"key":"2025122223464036200_bib29","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"2025122223464036200_bib30","doi-asserted-by":"publisher","first-page":"e0257606","DOI":"10.1371\/journal.pone.0257606","article-title":"Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Suwabe","year":"2021","journal-title":"PLoS One"},{"key":"2025122223464036200_bib31","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1136\/bmjopen-2019-032620","article-title":"Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis","volume":"10","author":"Griffiths","year":"2020","journal-title":"BMJ Open"},{"key":"2025122223464036200_bib32","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S2468-1253(24)00094-3","article-title":"Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework","volume":"9","author":"Duijzer","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025122223464036200_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/tri.12875","article-title":"Center is an important indicator for choice of invasive therapy in polycystic liver disease","volume":"30","author":"D'Agnolo","year":"2017","journal-title":"Transpl Int"},{"key":"2025122223464036200_bib34","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jhep.2023.02.012","article-title":"Issues in multi-organ transplantation of the liver with kidney or heart in polycystic liver-kidney disease or congenital heart disease: current practices and immunological aspects","volume":"78","author":"Taner","year":"2023","journal-title":"J Hepatol"},{"key":"2025122223464036200_bib35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2214\/AJR.16.16130","article-title":"Efficacy and safety of aspiration sclerotherapy of simple hepatic cysts: a systematic review","volume":"208","author":"Wijnands","year":"2017","journal-title":"Am J Roentgenol"},{"key":"2025122223464036200_bib36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.xkme.2019.07.015","article-title":"Foam sclerotherapy for cyst volume reduction in autosomal dominant polycystic kidney disease: a prospective cohort study","volume":"1","author":"Iliuta","year":"2019","journal-title":"Kidney Med"},{"key":"2025122223464036200_bib37","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/ndt\/gfaf019","article-title":"Nephrectomy in autosomal dominant polycystic kidney disease: a consensus statement of the ERA Genes & Kidney Working Group","volume":"40","author":"Geertsema","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223464036200_bib38","doi-asserted-by":"publisher","first-page":"101670","DOI":"10.1016\/j.clinre.2021.101670","article-title":"Partial major hepatectomy with cyst fenestration for polycystic liver disease: indications, short and long-term outcomes","volume":"45","author":"Boillot","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025122223464036200_bib39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jamcollsurg.2015.12.051","article-title":"Outcomes and durability of hepatic reduction after combined partial hepatectomy and cyst fenestration for massive polycystic liver disease","volume":"223","author":"Chebib","year":"2016","journal-title":"J Am Coll Surg"},{"key":"2025122223464036200_bib40","doi-asserted-by":"publisher","first-page":"100118","DOI":"10.1016\/j.aohep.2019.06.019","article-title":"Preserving the organ donor pool and suprahepatic vena cava: case series of transverse hepatectomy for polycystic liver disease","volume":"20","author":"Smith","year":"2021","journal-title":"Ann Hepatol"},{"key":"2025122223464036200_bib41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.surg.2020.02.014","article-title":"Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease","volume":"168","author":"Bernts","year":"2020","journal-title":"Surgery"},{"key":"2025122223464036200_bib42","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/LVT.0000000000000414","article-title":"Policy corner: polycystic liver disease MELD exception update","volume":"30","author":"Mehta","year":"2024","journal-title":"Liver Transpl"},{"key":"2025122223464036200_bib43","article-title":"H5 ELAS MELD: manual","author":"Eurotransplant","year":"2023"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf159\/64044100\/gfaf159.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/1\/171\/64044100\/gfaf159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/1\/171\/64044100\/gfaf159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T04:46:50Z","timestamp":1766465210000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/1\/171\/8234306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,14]]},"published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf159","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,8,14]]}}}